The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy.
 
Jianjun Gao
Travel, Accommodations, Expenses - AstraZeneca
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Genentech; Inovio Pharmaceuticals; Janssen; Lilly; Merck; NCCN
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb; Janssen; Michael and Sherry Sutton Fund for Urothelial Cancer; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Neema Navai
No Relationships to Disclose
 
Matthew T. Campbell
Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Novartis; Pfizer
 
Rebecca Slack
No Relationships to Disclose
 
Charles Guo
No Relationships to Disclose
 
Ashish M. Kamat
Honoraria - Pacific Edge
Consulting or Advisory Role - Abbott Molecular; Heat Biologics; Merck; Photocure; Sanofi; Spectrum Pharmaceuticals; Telesta Therapeutics; Theralase
Research Funding - FKD Therapies; Heat Biologics; Merck; Photocure
 
Surena F. Matin
Consulting or Advisory Role - C-SATS; Peloton Therapeutics; Theracoat; Urogen pharma
Research Funding - AT&T
 
John N. Papadopoulos
No Relationships to Disclose
 
John C. Araujo
No Relationships to Disclose
 
Amishi Yogesh Shah
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jorge M Blando
No Relationships to Disclose
 
Luis M Vence
No Relationships to Disclose
 
Fei Duan
No Relationships to Disclose
 
Sreyashi Basu
No Relationships to Disclose
 
Shalini Singh
No Relationships to Disclose
 
Hao Zhao
No Relationships to Disclose
 
Colin P.N. Dinney
Consulting or Advisory Role - FKD Therapies; NCI
Research Funding - FKD Therapies; NCI
 
Padmanee Sharma
Stock and Other Ownership Interests - BioAtla; Constellation Pharmaceuticals; Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I); Oncolytics
Consulting or Advisory Role - Amgen; Amgen (I); Astellas Pharma; AstraZeneca; AstraZeneca (I); BioAtla; Bristol-Myers Squibb; Bristol-Myers Squibb (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); EMD Serono; EMD Serono (I); Evelo Therapeutics; Evelo Therapeutics (I); GlaxoSmithKline; GlaxoSmithKline (I); Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Merck Sharp & Dohme; Neon Therapeutics; Neon Therapeutics (I); Oncolytics; Pieris Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)